CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Novartis AG (NVS) / inclisiran
Forward catalyst · NVS

inclisiran

Sponsor Novartis AG · listed as NVS

READOUT Phase 3 Confidence: medium Source: clinicaltrials

inclisiran is a clinical-stage drug asset sponsored by Novartis AG, listed as NVS. CSA tracks 3 forward catalysts for it — the nearest is a readout expected Oct 26, 2026 (day precision, medium confidence), tied to trial NCT05360446. The asset is in Phase 3 and currently active not recruiting, studied in Coronary Artery Disease. It appears across 9 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-10-26
As disclosedOct 26, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05360446
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorNovartis Pharmaceuticals
Listed asNVS
Condition(s)Coronary Artery Disease

All tracked catalysts for inclisiran

DateEventConfidenceTrial
2026-10-26READOUTmediumNCT05360446
2026-10-31READOUTmediumNCT03705234
2027-02-11READOUTmediumNCT07102628
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More NVS catalysts